Skip to content
orbyd

Dossier · DNTH · Dormant

DNTH · Dianthus Therapeutics, Inc. · Stock research

MEDIUM Earnings inflection Catalyst · oncology-immunology

Last analysed ·

Current thesis

Single-asset complement biotech (claseprubart/DNTH103) broke out to a new 52-week high near $102 in July, reclaiming and extending well above the $81 March offering shelf as the Sanofi same-mechanism CIDP fear faded and analyst PTs clustered to a $117.82 average. The re-rate leg is running into a five-month data vacuum no binary until CAPTIVATE Part B topline guided by end-2026 with dilution-on-pop risk near round-number highs.

Invalidation trigger

A weekly close below $81 reclaims the March-2026 offering shelf and fails the July breakout back into the pre-breakout range; secondary breaks: randomized CAPTIVATE Part B (end-2026) does not confirm the open-label INCAT responder signal (Sanofi riliprubart read-through materializes), or the complement-autoimmune theme flips SATURATED.

Thesis status

Open commitment catalyst 76d agoscored if the trigger above fires How this is scored →

Latest analysis and events for DNTH —

As of 2026-07-15, orbyd's latest analysis for Dianthus Therapeutics, Inc. (DNTH): Single-asset complement biotech (claseprubart/DNTH103) broke out to a new 52-week high near $102 in July, reclaiming and extending well above the $81 March offering shelf as the Sanofi same-mechanism CIDP fear faded and analyst PTs clustered to a $117.82 average. The re-rate leg is running into a five-month data vacuum no binary until CAPTIVATE Part B topline guided by end-2026 with dilution-on-pop risk near round-number highs.

Invalidation trigger: A weekly close below $81 reclaims the March-2026 offering shelf and fails the July breakout back into the pre-breakout range; secondary breaks: randomized CAPTIVATE Part B (end-2026) does not confirm the open-label INCAT responder signal (Sanofi riliprubart read-through materializes), or the complement-autoimmune theme flips SATURATED.

Most recent dated event on file: — catalyst 76d ago.

Current Thesis

Claseprubart (DNTH103), a selective antibody that binds only the active form of C1s to block the classical complement pathway while sparing the lectin and alternative arms, is the single asset this ~$5.4B market cap rests on. After basing on the $81.00 March offering shelf through Q2, the stock broke out in July: a new 52-week high of $102.24 on 2026-07-09, closing near $100.03, above a rising 50-DMA ($87.16) and 200-DMA ($71.17). The drivers were the Sanofi same-mechanism CIDP fear fading and a cluster of analyst price-target hikes (Moderate Buy consensus, $117.82 average). What that move actually is: a pre-data re-rate into a vacuum. The next hard binary is randomized CAPTIVATE Part B topline, guided only to "by end of 2026," and the gMG Phase 3 readout is not until 2H'28. The tape is pricing Part B success roughly five months early, against a live mechanism overhang and dilution-on-pop risk near round-number highs. Continuation holds while the breakout does, but a fresh entry at +40% above the 200-DMA into a catalyst-free stretch is late in the re-rate, not the accumulation window.

Bullish and bearish views on Dianthus Therapeutics, Inc.

The model's bull view on Dianthus Therapeutics, Inc. (DNTH), in brief: Breakout confirmed above the offering shelf. The bear view: A same-target competitor just failed. Sanofi's riliprubart, also a selective anti-activated-C1s antibody, had its MOBILIZE Phase 3 halted 2026-06-10 for insufficient efficacy in refractory CIDP. The CAPTIVATE GO is open-label responder data with no placebo arm precisely what… Both cases follow in full.

Bull Case

  • Breakout confirmed above the offering shelf. New 52-week high $102.24 on 2026-07-09;
  • CAPTIVATE interim looks strong. 75% of the first 40 Part A completers were confirmed responders on adjusted INCAT; early GO decision announced 2026-03-09. The de-risked design shrinks Part A to ≤256 patients (from 480) and Part B to 128 (from 192), pulling randomized topline into end-2026.
  • gMG Phase 2 MaGic clean. Statistically significant improvement across five key endpoints at Week 13 for 300mg Q2W, onset from week 1, no drug-related serious AEs the best-in-class safety pitch versus C5 inhibitors.
  • Funded through the readout. ~$1.2B cash at 2026-03-31, runway guided into 2030; the dilution event already cleared at $81.
  • Sell-side aligned. Moderate Buy consensus, average target $117.82 (~18% above spot), rated 1 Strong Buy / 12 Buy / 1 Sell.
  • Convenience angle. Phase 3 carries 300mg/2mL SC Q2W and Q4W arms monthly dosing is a differentiator if efficacy holds.

Bear Case

  • A same-target competitor just failed. Sanofi's riliprubart, also a selective anti-activated-C1s antibody, had its MOBILIZE Phase 3 halted 2026-06-10 for insufficient efficacy in refractory CIDP. The CAPTIVATE GO is open-label responder data with no placebo arm precisely what MOBILIZE failed on. Randomized Part B is the real test and does not read until end-2026.
  • Single molecule, one fuse. A negative randomized readout craters CIDP, gMG, and MMN optionality on the same day. No diversification cushion.
  • Stretched. +40% above the 200-DMA ($71.17), +15% above the 50-DMA ($87.16), at a fresh high, into a five-month data vacuum. Momentum with no near-term catalyst mean-reverts on any tape wobble.
  • Dilution-on-pop risk. After a re-rate to $100, an ATM or follow-on near round-number highs is the base case for a cash-burning clinical biotech.
  • Valuation. ~$5.4B on a single Phase 3 asset with unproven placebo-adjusted efficacy.
  • MG is years out. gMG Phase 3 topline is guided to 2H'28 not a 2026 driver.

Setup & Price Structure

Spot ~$100.03 (2026-07-09), intraday high $102.24. The moving-average stack is fully bullish and rising: price > 50-DMA ($87.16) > 200-DMA ($71.17). The 52-week range runs roughly $16.64 to $102.24, about a 6x. The $81.00 March-12 offering price now sits ~19% below spot as reclaimed support; the breakout and extension confirm the shelf held through the Sanofi scare. Nearest support is the prior consolidation near $87–90 (the 50-DMA), then the $81 shelf. This is a clean momentum breakout to new highs, but the extension is elevated and there is no dated catalyst to feed it near-term absent fresh news the path of least resistance is a drift into the 50-DMA. Volume quality on the breakout is the tell: a thin push to new highs in a data vacuum is a fade, not a base.

Catalyst Calendar (next 30 days)

  • No dated binary catalyst inside the 30-day window.
  • CAPTIVATE Part B randomized topline: guidance "by end of 2026" (~Q4-26, undated).
  • gMG Phase 3 initiation: guided mid-2026 an operational milestone, not a data event; watch for an initiation press release.
  • Q2-26 results / cash-runway update: biotech cadence puts this early-to-mid August (est. ~2026-08-11, unconfirmed), at the edge of the window; watch for any ATM disclosure.
  • Peer read-through: complement/FcRn autoimmune data from ARGX, IMVT, or UCB can reprice DNTH independent of company news.

What Would Change Our Mind

  • A weekly close below $81 reclaims the March-2026 offering shelf and fails the July breakout back into the pre-breakout range the re-rate is over.
  • Randomized CAPTIVATE Part B (end-2026) missing or failing to confirm the open-label INCAT responder signal the Sanofi read-through materializing on placebo-controlled data resets the entire platform.
  • An equity raise or ATM priced meaningfully below spot signals management is treating the pop as a financing window rather than a value inflection.
  • A theme flip to SATURATED mainstream complement-biotech coverage, peer crowding with no fresh company catalyst.
  • On the other side, a de-risking event (a clean Part B interim, a well-enrolled gMG Phase 3 start, or continued PT expansion above $130 on real volume) re-arms the accumulation case on a pullback toward the 50-DMA.

Correlation Notes

  • Classical-complement / autoimmune complex: two-way read-through with ARGX (FcRn, Vyvgart — the approved CIDP incumbent), IMVT (batoclimab / IMVT-1402), UCB (zilucoplan), and Sanofi (riliprubart — the 2026-06-10 failure). A peer CIDP or gMG print moves DNTH the same session.
  • SMID-biotech beta: sensitive to XBI and the rate regime; a single-asset clinical name gaps on risk-off tape regardless of company news.
  • The Sanofi mechanism overhang is the dominant idiosyncratic driver any further activated-C1s or classical-complement CIDP data, positive or negative, reads directly into claseprubart until Part B settles it.

Notes

  • Single-molecule platform negative gMG readout craters CIDP/MMN optionality same day; size as binary.
  • Last decision 2026-04-19 was current refresh is the first real read.
  • No price context piped this session; next watchlist scan must fill spot/DMA stack/IV before any sizing decision.
  • AAN 2026-05-04/07 can reprice DNTH off ARGX/UCB/IMVT/JNJ competitor readouts independent of company-specific news.
  • Equity-raise-on-pop is base case post-positive Phase 2; don't chase first green day without watching block-trade tape.
  • Single-molecule platform negative gMG readout craters CIDP/MMN optionality same day; size as binary not as diversified biotech.
  • No price context piped this session (2nd consecutive refresh) next watchlist scan MUST populate spot vs $98 PT
  • 20/50/200-DMA stack
  • RSI
  • 52-wk range
  • IV rank before any sizing decision.
  • AAN 2026-05-04 through 2026-05-07 can reprice DNTH off ARGX/UCB/IMVT/JNJ competitor readouts independent of company-specific news treat as exogenous catalyst.
  • Equity-raise-on-pop is base case post any positive Phase 2; do NOT chase first green day open without watching block-trade tape and ATM filing radar.
  • Last real synthesis 2026-04-20; prior 2026-04-19 decision was. This refresh supersedes the 2026-04-19 stub.
  • Theme classification narrowed 2026-04-21 from 3 themes to 1 (rare-disease-approvals only) monitor for re-broadening which would signal sector bid extending.
  • T-3 trading days into any gMG topline PR window = mandatory flatten; binary risk is not our edge.
  • MAJOR REFRESH 2026-06-07: prior dossier's central binary (H2-2026 gMG topline) is OBSOLETE MaGic gMG Phase 2 read POSITIVE 2025-09-08; CIDP CAPTIVATE hit early Phase 3 GO; stock already re-rated ~630% YoY. Drug now named claseprubart (DNTH103).
  • $81.00 = the line that matters: March-12-2026 offering price (8,470,989 sh + 402,468 pre-funded warrants, $719M gross), institutional cost basis. Spot $80.51 (2026-06-05) sitting on it. Weekly close below on >1.5x vol = distribution / thesis break.
  • Sell-side fully caught up: consensus PT $121.17, Strong Buy (12 analysts). RJ $63→$123 + upgrade to Strong Buy 2026-03-10; HC Wainwright $47→$130; Wells Fargo initiate Overweight 2026-03-19. Buying here = buying AFTER the narrative published.
  • Balance sheet fortress: $514.4M cash 2025-12-31 + ~$719M gross March raise = ~$1.1B+ pro forma, runway extended past prior 'into 2028' guide. No near-term financing overhang.
  • Next true binary = MMN MoMeNtum Phase 2 topline 2H-26 (no firm date). Phase 3 gMG topline is 2H-28 years of holding risk. Catalyst GAP in next 30d argues patience over chase.
  • Single-molecule platform: negative MMN or CAPTIVATE Part B miss craters CIDP/MMN optionality same day size as binary, not diversified biotech.
  • Insider distribution at highs: EVP R&D Randhawa sold ~$2.4M (26,530 sh @ $89.17–91.96) 2026-06-01 under 10b5-1; inducement options struck $89.45 same day. Not panic, but no one adding at $81.
  • Beta 0.07 idiosyncratic, NOT an XBI-beta vehicle. Moves on company catalysts; weak sector sympathy bid.
  • Theme reclassified to MATURING: narrative accelerated, sell-side caught up, now consolidating. Fresh upside needs a NEW catalyst, not continuation.
  • FDA dropped ANA screening criterion across claseprubart program (drug-induced-lupus theoretical concern resolved) minor enrollment tailwind.
  • $81.00 = the line that matters: 2026-03-12 offering price (8,470,989 sh + 402,468 pre-funded warrants, $719M gross), institutional cost basis. Held the Sanofi-fail dip (≈$67-68 intraday low ~2026-06-10) and recovered to $82.49 (2026-06-18). Weekly close below on >1.5x vol = distribution break.
  • Mechanism read-through is now PROVEN, not theoretical: Sanofi riliprubart (same selective anti-activated-C1s target) failed MOBILIZE Phase 3 in refractory CIDP 2026-06-10; DNTH -16% same day on zero company news. CAPTIVATE early GO was OPEN-LABEL responder data (no placebo) randomized Part B is the real test of the same question Sanofi lost.
  • Single-molecule platform a negative randomized CIDP or MMN print impairs gMG/CIDP/MMN optionality simultaneously; size as binary, not diversified biotech.
  • No price-piped IV/DMA stack this session next watchlist scan MUST populate spot vs $121-130 PT, 20/50/200-DMA stack, RSI, 52-wk range ($16.64-$96.50), IV rank before any sizing.
  • T-3 trading days into any topline PR window (MMN / CAPTIVATE randomized, 2H-26) = mandatory flatten; binary risk is not the edge.
  • Re-rate spent + sell-side fully caught up (Strong Buy, ~$121-130 consensus). Re-entry requires a fresh clean base (second hold of $81, breakout >$90 on volume) into a DATED catalyst, not a chase at the shelf.
  • Q2 2026 financial update est. ~early August 2026 (prior-year cadence); watch for ATM/raise-on-strength given the V-recovery back above $81.
  • Theme re-broadened 2026-06-21 from rare-disease-approvals only to add complement-biotech + autoimmune-neuromuscular mechanism-class beta to SNY/ARGX/UCB is now demonstrated by the 2026-06-10 Sanofi move.
  • MAJOR REFRESH 2026-07-12: prior DORMANT/LOW read is stale DNTH broke out from ~$82 (2026-06-18) to a new 52-wk high $102.24 (2026-07-09), reclaiming and extending above the $81 offering shelf. Now +40% above 200-DMA ($71.17), +15% above 50-DMA ($87.16). Re-rate re-accelerated on faded Sanofi fear + clustered analyst PT hikes (avg $117.82).
  • Single-molecule platform: one negative randomized readout craters CIDP/gMG/MMN optionality same day size any exposure as a binary, not as diversified biotech.
  • Next hard binary is CAPTIVATE Part B randomized topline, guided 'by end of 2026' (undated). No dated catalyst in the next 30d the July move is a pre-data re-rate into a vacuum.
  • Dilution-on-pop is base case: after a run to $100, an ATM/follow-on near highs is the standard playbook for a cash-burning clinical biotech ($1.2B cash at 2026-03-31, runway into 2030). Watch block-trade tape and ATM filings before chasing.
  • Sanofi riliprubart MOBILIZE Phase 3 (same activated-C1s mechanism) failed refractory CIDP 2026-06-10 the overhang only clears with placebo-controlled Part B data.
  • gMG Phase 3 topline not until 2H'28; MG optionality is years out, not a 2026 driver.
  • T-3 trading days into any topline PR window = binary risk, not the edge here.
  • Consensus 1 Strong Buy / 12 Buy / 1 Sell as of 2026-07-09; spot ~$100 vs $117.82 avg PT leaves ~18% to target but sell-side is fully caught up.

Related · shared themes

KYMR

Kymera Therapeutics, Inc.

Oral STAT6 degrader (KT-621) re-rated on early BROADEN2 enrollment (6/25) and the $10.9B AbbVie–Apogee read-through, but the analyst upgrade cycle topped with RBC's 7/13 downgrade to neutral and the binary topline is 2H-2026 a maturing, stretched theme better bought on a pullback to the $100 shelf than chased into the catalyst gap.

LOW

SYRE

Spyre Therapeutics, Inc.

Two of three lead binaries (SPY001, SPY002 anti-TL1A) printed potential best-in-class; the stock absorbed a ~$399.7M director-fund block sale and sits back near its ~$102 ATH (~$95). Next legs SPY003 IL-23 Part A (guided mid-2026, overdue) and SPY072 RA topline (accelerated to Q3) are the near-term binaries. Platform de-risked, but distribution flags plus ~1:1 R/R to $100–135 targets argue probe-only into an all-time high.

LOW

TNGX

Tango Therapeutics, Inc.

Post-data digestion, not acceleration: the 92% ORR combo print is fully paid for and the tape has faded from $32.90 to ~$27.7, below the $30.00 June secondary. Sell-side keeps marking up (JPM Overweight $46 on 7/15, Mizuho $40 on 7/17) into a falling price a divergence that historically resolves toward price. Next hard data is ESMO in October.

LOW

PSNL

Personalis, Inc.

The MRD story has been overtaken by a live sale process: StreetInsider reported 2026-07-17 that Personalis retained Centerview, TD Securities and Cooley after takeover interest from Merck (already a >10% holder and 19% of Q1 revenue) plus two other suitors. Price broke to a $16.39 52-week high; Needham $17 and TD Cowen $18 now sit above the tape. Aug-4 Q2 is the next hard date.

HIGH

See also · stocks to watch

oncology and immunology stocks to watch